Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?

Almost all currently available treatments for inflammatory bowel disease (IBD) act by inhibiting inflammation, often blocking specific inflammatory molecules. However, given the infectious and neoplastic disease burden associated with chronic immunosuppressive therapy, the goal of attaining mucosal healing without immunosuppression is attractive. The absence of treatments that directly promote mucosal healing and regeneration in IBD could be linked to the lack of understanding of the underlying pathways. The range of potential strategies to achieve mucosal healing is diverse. However, the targeting of regenerative mechanisms has not yet been achieved for IBD. Stem cells provide hope as a regenerative treatment and are used in limited clinical situations. Growth factors are available for the treatment of short bowel syndrome but have not yet been applied in IBD. The therapeutic application of organoid culture and stem cell therapy to generate new intestinal tissue could provide a novel mechanism to restore barrier function in IBD. Furthermore, blocking key effectors of barrier dysfunction (such as MLCK or damage-associated molecular pattern molecules) has shown promise in experimental IBD. Here, we review the diversity of molecular targets available to directly promote mucosal healing, experimental models to identify new potential pathways and some of the anticipated potential therapies for IBD. Attaining mucosal healing without immunosuppression is an attractive option for the treatment of inflammatory bowel disease (IBD). This Review describes the mechanisms of mucosal healing and how they might be altered in IBD and discusses potential therapeutic approaches to promote mucosal healing and regeneration.

Automated summary

Current treatments for inflammatory bowel disease (IBD) mainly focus on inhibiting inflammation, but the use of immunosuppressive therapy can lead to infectious and neoplastic diseases. Therefore, finding a way to achieve mucosal healing without immunosuppression is important. The lack of treatments that directly promote mucosal healing and regeneration in IBD may be due to a lack of understanding of the underlying pathways. Stem cells, growth factors, and organoid culture and stem cell therapy are potential novel mechanisms to restore barrier function in IBD.